Dose effects of CitraPeak (glucosyl‑hesperidin) on exercise, blood flow, stress, and thinking
Dose-Response Impact of Glucosyl-Hesperidin (CitraPeak) on Exercise Performance, Blood Flow, Stress, Cognition, and Other Perceptual Indicators
This test tries daily CitraPeak (glucosyl‑hesperidin) at two doses to see if it helps healthy, recreationally active adults (18–50) improve exercise performance, recovery, blood flow, mood, and cognition.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 50 Years |
| Sex | All |
| Sponsor | Lindenwood University Academic / other |
| Locations | 1 site (Saint Charles, Missouri) |
| Trial ID | NCT06672952 on ClinicalTrials.gov |
What this trial studies
This randomized, double‑blind, placebo‑controlled trial will enroll about 60 healthy, recreationally active adults aged 18–50 and assign them by sex and baseline fat‑free mass to placebo, 200 mg, or 400 mg CitraPeak taken daily for 8 weeks. Participants will complete multiple in‑person visits for exercise performance tests, blood flow measurements, cognitive assessments, mood and sleep questionnaires, and metabolic/fuel use measures, with adherence tracked via supplementation logs. The design permits comparison of dose‑dependent effects on aerobic/anaerobic capacity, recovery indicators, nitric oxide–related blood flow, and perceptual outcomes. Blinding and a placebo control aim to isolate the supplement effect from expectation and training variability.
Who should consider this trial
Good fit: Ideal candidates are healthy, free‑living adults aged 18–50 who complete at least 180 minutes of moderate to vigorous exercise weekly, have a BMI between 25.0 and 30.0 kg/m2 (with the study cohort mean BMI maintained below 27.0), and are willing to attend multiple visits and take a daily supplement for 8 weeks.
Not a fit: People outside the 18–50 age range, those with BMI outside the 25–30 kg/m2 enrollment window, sedentary individuals, or anyone with cardiovascular, respiratory, metabolic, immune, psychiatric, or significant musculoskeletal disease are unlikely to match the enrolled population and may not benefit.
Why it matters
Potential benefit: If effective, the supplement could modestly improve exercise performance, recovery, blood flow, mood, and cognitive function for recreationally active adults.
How similar studies have performed: Some small studies of citrus flavonoids and hesperidin derivatives have suggested improvements in endothelial function, blood flow, and recovery, but evidence for this specific glucosyl‑hesperidin formulation and dose range is limited and not definitive.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Participants who are between 18 - 50 years of age 2. Body mass index values will range from \>25.0 \< 30.0 kg/m2 3. The average body mass index for entire study cohort will be less than 27.0 kg/m2. As such an ongoing calculation of the recruited cohort's mean body mass index will be maintained and people will only be randomized into the study if the average cohort body mass index value does not exceed 27.0 kg/m2 4. Free-living and independent 5. In good health absent of being overweight or mildly obese with no other signs or symptoms of cardiovascular, respiratory, metabolic, immune, psychiatric, or musculoskeletal disease or disorders 6. Willingness to maintain consistent sleep duration the evening before study visits 7. Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, and carry out all study-related procedures 8. Regular completion of at least 180 minutes of moderate to vigorous exercise per week for the past 6 months Exclusion Criteria: 1. Not currently completing at least 180 minutes of moderate to vigorous exercise per week for the past 6 months 2. Positive medical history and/or is currently being treated for some form of heart disease, cardiovascular disease 3. Currently being treated for kidney disease, renal failure, or has dialysis performed on regular intervals 4. Has liver disease or some form of clinically diagnosed hepatic impairment 5. Diagnosed with having Type I or Type II diabetes (determined as fasting blood glucose \> 126 mg/dL) 6. Diagnosed with or is being treated for some form of thyroid disease 7. Diagnosed with major affective disorder or other psychiatric disorder that required hospitalization in the prior year 8. Diagnosed with some form of immune disorder (i.e., HIV/AIDS) 9. History of cancer (except localized skin cancer without metastases or in situ cervical cancer within 5 years prior to screening visit). 10. Participant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea) 11. Positive medical history for any neurological condition or neurological disease 12. Currently prescribed a statin drugs (i.e., Lipitor, Livalo, Crestor, Zocor, etc.) or any hypertension medications (i.e., Beta-blockers, ACE Inhibitors, Alpha blockers, Vasodilators, etc.) 13. Current smoker (average of \> 1 pack per day within the past 3 months) has quit within the past six months. This includes all forms of nicotine 14. Intake of any drugs (prescribed or over the counter) or dietary supplements that are known or are purported to weight loss such as thermogenics, hydroxycitric acid, ephedra, capsaicin, etc. 15. Participants who are lactating, pregnant or planning to become pregnant 16. Have a known sensitivity or allergy to any of the study products 17. History of alcohol or substance abuse in the 12 months prior to screening 18. Receipt or use of an investigational product in another research study within 30 days of beginning the study protocol 19. Any orthopedic limitation that would prevent participation in a general fitness program 20. Any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the participant or the quality of the study data
Where this trial is running
Saint Charles, Missouri
- Lindenwood University — Saint Charles, Missouri, United States (Recruiting)
Study contacts
- Principal investigator: Chad M Kerksick, PhD — Lindenwood University
- Study coordinator: Anthony M Hagele, MS
- Email: ahagele@lindenwood.edu
- Phone: 636-949-4785
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.